Cochrane · systematic review · CD006602
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children
Andabaka, T, Nickerson, JW, Rojas‐Reyes, MX, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
Acute Respiratory InfectionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
13
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 7.1%Very low 1 · 7.1%Low 1 · 7.1%Moderate 6 · 42.9%High 5 · 35.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Palivizumab compared to placebo for high risk of severe respiratory syncytial virus infection
Population: patients at high risk of severe respiratory syncytial virus infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Hospitalisation for RSV infection Palivizumab vs placebo | RR 0.49 [0.37, 0.64] | 3 studies · 2831 participants | High |
All‐cause mortality Palivizumab vs placebo | RR 0.69 [0.42, 1.15] | 3 studies · 2831 participants | Moderate |
Total RSV hospital days per 100 children Palivizumab vs placebo | no estimate extracted | 2 studies · 2789 participants | Moderate |
Admission to ICU Palivizumab vs placebo | RR 0.5 [0.3, 0.81] | 2 studies · 2789 participants | High |
Mechanical ventilation for RSV infection Palivizumab vs placebo | RR 1.1 [0.2, 6.09] | 2 studies · 2789 participants | Very low Downgraded: inconsistency |
Supplemental oxygen therapy for RSV infection Palivizumab vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Number of children reporting any SAE Palivizumab vs placebo | RR 0.88 [0.8, 0.96] | 1 study · 1287 participants | High |
Palivizumab compared to motavizumab for high risk of severe respiratory syncytial virus infection
Population: patients at high risk of severe respiratory syncytial virus infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Hospitalisation for RSV infection Palivizumab vs motavizumab | RR 1.36 [0.97, 1.9] | 2 studies · 7870 participants | Moderate |
All‐cause mortality Palivizumab vs motavizumab | RR 0.74 [0.38, 1.43] | 4 studies · 8265 participants | Moderate |
Total RSV hospital days per 100 children Palivizumab vs motavizumab | no estimate extracted | 2 studies · 7870 participants | Low |
Admission to ICU Palivizumab vs motavizumab | RR 1.68 [0.89, 3.19] | 2 studies · 7870 participants | Moderate |
Mechanical ventilation for RSV infection Palivizumab vs motavizumab | RR 3.79 [1.26, 11.42] | 2 studies · 7870 participants | High |
Supplemental oxygen therapy for RSV infection Palivizumab vs motavizumab | RR 1.49 [0.98, 2.26] | 2 studies · 7870 participants | Moderate |
Number of children reporting any SAE Palivizumab vs motavizumab | RR 1.04 [0.96, 1.13] | 4 studies · 8238 participants | High |